港股異動 | 現代牙科(3600.HK)飆漲逾18% 2020年核心業務溢利同比增長36.9%
格隆匯4月1日丨現代牙科(3600.HK)大幅拉昇至18.41%,報2.38港元創近3年新高價,暫成交1881萬港元,總市值23億港元。現代牙科3月30日公吿,2020年度的收益約為17.3億港元,同比下降5.8%;來自核心業務的溢利約為2.24億港元,同比增長36.9%。公司普通權益持有人應占每股盈利11.2港仙。集團把握上半年被抑制的產品及服務需求,以及行業加速整合帶來的重大機遇,從而令集團的財務業績實現空前反轉。另外,於3月31日該公司斥資43.22萬港元回購24.1萬股,回購價格為每股1.76-1.83港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.